As the coronavirus disease 2019 (COVID-19) pandemic continues with no clear end in sight, physicians, policymakers, and the public alike are searching for answers about where we are headed. Several independent models of disease spread and mortality have been published, and they often came to different conclusions. Modeling COVID-19 has proven to be a complex and difficult endeavor.

It is useful for this discussion to differentiate between epidemiologic and individual prediction models. The former category predicts outcomes for a population, such as a state or country, whereas the latter category predicts outcomes for individual patients. Each type of model has a set of constraints involved in its design and use.

The Centers for Disease Control and Prevention publish an ensemble forecast of national deaths based on 19 independently developed models, all of which fall into the epidemiologic category.[@bib1] Predicting mortality in a population over time is a very complicated task and requires a number of assumptions to be made. Of note, given its novelty, the biological properties of this virus are imperfectly understood. For instance, the duration and degree of immunity conferred by exposure will determine the likelihood and intensity of recurrent outbreaks. Presumably to mitigate this issue, the models in the Centers for Disease Control and Prevention ensemble make projections over a 4-week period.

Mortality is fundamentally a function of the fatality rate and spread of disease, each of which is driven by a multitude of factors. Fatality rates depend in part on population demographics and availability of testing, and currently available estimates vary widely across countries.[@bib2] Disease spread depends heavily on the prevalence of COVID-19, which is not precisely known, and on policy interventions such as social distancing, which are a moving target and not intrinsically measurable. Policy changes rapidly, and as Memorial Day crowds show, the degree of compliance with restrictions is also unknown. Emerging studies using antibody tests suggest that prevalence is likely highly underestimated,[@bib3] but these serologic tests are themselves imperfect, and validated performances can vary broadly depending on the specific assay that is used.[@bib4]

To get around this, models either use proxies or make assumptions about the degree and effectiveness of social distancing. For example, the University of Texas model uses phone geolocation data as a proxy for social distancing and assumes the intervention remains constant across the forecasted time period.[@bib5] Conversely, the Columbia model considers three scenarios, all of which assume a flat 20% reduction in contact rates for each week of stay-at-home orders, with either a one-time 10% increase in contact rates, a weekly 10% increase in contact rates, or no change in contact rates after stay-at-home orders are lifted.[@bib6]

These design choices significantly alter predicted outcomes, and it is impossible to know which assumptions will most closely match reality. Assumptions may also change over time as information emerges and their performance is reassessed; for example, the Columbia model updated contact tracing assumptions to the current parameters to model loosening social distancing restrictions as states reopen.[@bib6]

Individual predictions models, which make diagnostic or prognostic predictions about a disease based on a patient's unique set of characteristics, have their own set of challenges. The general workflow involved in developing such a model is as follows: 1) the outcome of interest is defined; 2) relevant predictors or risk factors are identified; 3) the effects of each predictor variable are estimated, for example in a regression analysis; and 4) the model is validated.[@bib7] Validation is comprised of discrimination and calibration, which are the ability to separate individuals who experience the outcome from those who do not and how well the predicted probabilities match reality, respectively. Each of these steps presents a challenge in the context of any emerging disease, such as COVID-19.

First, many clinically useful outcomes of interest, such as progression to the ICU, need for a ventilator, or death, are time-to-event; therefore, we may need to consider censoring. In addition, relevant risk factors are still emerging, and many are difficult to measure, such as travel history and symptom duration (symptom onset is often uncertain). We can identify candidate predictors by generalizing from models of other respiratory viruses, but these need to be validated, and their relevance may vary depending on the population that is studied.

Once an outcome is defined and predictors are selected, we need a large data set of patients that includes all the desired features; therefore, we can estimate regression coefficients or train a machine learning algorithm. Thanks to electronic medical records, an enormous amount of information will eventually be available, but these data need to be collected and cleaned for analysis. Dimensionality of the data also becomes an issue: as more predictors are considered, a greater number of observations is required to assess significance (a common rule of thumb being 10 observations per predictor). Validation of the model is also critical. We can use the training data set itself for internal validation using methods such as bootstrapping and 10-fold cross-validation. Ideally, we would also externally validate models on an independent cohort, but this takes time and is not always done.

When considering the value of COVID-19 models, there are several questions we must consider. The strength of epidemiologic models is that they allow us to flexibly consider a range of possible scenarios and examine how outcomes change as our assumptions shift. No single model represents truth, but the combined spectrum of projections can guide us. Similarly, individual models can help physicians design a management plan that has the best predicted outcome for each unique patient. A model cannot and does not have to be perfect, but it should be a useful approximation. The pandemic raises an interesting question: is it more ethical to use a model that is not validated, or to press forward with no model? As a corollary, if a clinical model has been extensively internally validated, but not externally validated, should it be used in clinical practice? Models can be helpful decision-making aids during our uncertain future, but we must keep in mind the assumptions that were built in and the quality of the underlying data.

**Other contributions:** We thank Stephanie S. Kocian, MAT, MA, for her assistance with the manuscript.

**FINANCIAL/NONFINANCIAL DISCLOSURES:** None declared.
